GlassScriptPhysician profile
Ryan P Crenshaw
NPI 1447342746
$1,817.01
in general payments reported to CMS, 2019-2025
20 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $187 · 2021: $257 · 2022: $164 · 2023: $270 · 2024: $285 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $375.09 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $244.77 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $221.50 | 2019-2024 | Skyrizi, Rinvoq |
| Pfizer INC. | $210.78 | 2019-2025 | |
| Celgene Corporation | $119.92 | 2022-2024 | Zeposia |
| Olympus America INC. | $112.77 | 2019 | |
| Genzyme Corporation | $91.51 | 2023-2025 | |
| Braintree Laboratories, INC. | $88.96 | 2020-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $53.75 | 2019-2020 | |
| Gilead Sciences, INC. | $48.66 | 2020-2022 | |
| Celltrion USA INC. | $47.89 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $42.52 | 2022-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $35.28 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $24.74 | 2025 | Sucraid |
| Otsuka America Pharmaceutical, INC. | $18.59 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $18.16 | 2020 | |
| Lilly USA, LLC | $17.64 | 2024 | Omvoh |
| Glaxosmithkline, LLC. | $15.70 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.60 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Crenshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.